In today’s briefing:
- Keymed Biosciences (2162.HK) – The Potential for Doubling Valuation and the Corresponding Risks
Keymed Biosciences (2162.HK) – The Potential for Doubling Valuation and the Corresponding Risks
- Due to doctors’ poor diagnosis/limited affordability, commercialization prospects of China autoimmune disease market could be much lower than expected. Internationalization is inevitable, but Keymed is lack of cash for MRCT.
- For CM310 and CM326, their total sales in China could be less than RMB2 billion. For CMG901, it is hard to say if Claudin 18.2 (ADC) would finally be successful.
- As long as Keymed can successfully develop either CM310 or CM326 (key premise), even temporarily only commercializing in the domestic market, the Company has the potential to double in valuation.
Before it’s here, it’s on Smartkarma
